BioVersys Makes First Swiss IPO of 2025 with CHF216M Valuation

In a significant milestone for Switzerland's biotech sector, Basel-based BioVersys has marked the first initial public offering (IPO) of 2025 on the SIX Swiss Exchange. The company's debut on February 7th represents a major achievement for the Swiss biotech ecosystem and underscores the country's position as a leading hub for pharmaceutical innovation.

The IPO launched with shares trading at CHF36.50, establishing a market capitalization of CHF216 million. BioVersys successfully offered approximately 2.1 million shares through a bookbuilding process, with an additional over-allotment option of nearly 139,000 shares. The company raised CHF80 million in proceeds, demonstrating strong investor confidence in its innovative approach to antibiotic development.

BioVersys has established itself as a pioneer in addressing life-threatening infectious diseases. The company's flagship product, BV100, targets hospital infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB). The substantial IPO proceeds will primarily fund BV100's progression through clinical phase III trials, marking a crucial step in bringing this innovative treatment to market.

The IPO has attracted significant strategic investors, including the Glaxo Group, which invested CHF3.5 million, and the AMR Action Fund. CEO Marc Gitzinger highlighted this as a crucial milestone in the company's growth strategy. The successful listing on SIX Swiss Exchange, rather than overseas markets, reinforces Switzerland's attractiveness as a biotech financing hub, as noted by exchange head Bjørn Sibbern.